Gastric Cancer Survival Without Chemotherapy

Development of a Staging System and Survival Prediction Model for Advanced Gastric Cancer Patients Without Adjuvant Treatment After Curative Gastrectomy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05125614

Enrollment

342

Registered

2021-11-18

Start date

2020-05-01

Completion date

2021-07-01

Last updated

2021-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

Gastric cancer, Adjuvant chemotherapy, Overall survival, Nomogram, Prediction

Brief summary

This study is observational study to analyze the actual overall survival of the patients who did not receive adjuvant chemotherapy after curative gastrectomy for gastric cancer. The investigators developed prediction model for the overall survival of these patients and validated.

Detailed description

Adjuvant chemotherapy (AC) after curative gastrectomy is the standard treatment for patients with locally advanced gastric adenocarcinoma in East Asia; however, for various reasons, some patients do not receive this treatment. The aim of this study was to develop a system that reflects the survival rate of patients without AC. A survival prediction model was developed based on the modified staging system and risk factors for overall survival (OS), which were examined using the Cox proportional hazards regression model. The model was validated for the power of prediction and discrimination, compared with the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th edition; it was externally validated using an independent dataset. the newly developed survival prediction model improves the accuracy of OS prediction for stage II and III gastric cancer patients without AC after curative gastrectomy.

Interventions

OTHERNo adjuvant chemotherapy

There is no intervention differences between 2 groups. We analyzed the data of the patients who did not receive adjuvant chemotherapy.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Inclusion criteria

* histologically confirmed primary gastric adenocarcinoma * curative R0 resection with D2 lymph node dissection * pathologic stage II or III gastric cancer

Exclusion criteria

* Patients who received neoadjuvant or AC treatment * follow-up loss or death within 30 days of surgery * completion of total gastrectomy * other malignancy within 5 years before gastrectomy

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	June-01-2021	Overall survival of the patients

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026